Fibrosis / bjúgur

P.sup.1-(2'-deoxycytidine 5'-)P.sup.4-(uridine 5'-)tetraphosphate, tetra-(alkali metal) salt, for treating cystic fibrosis

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

TECHNICAL FIELD This invention relates to a method of treating edematous retinal disorders. Specifically, this invention relates to a method of removing pathological fluid accumulation in subretinal and intra-retinal spaces. This invention also relates to dinucleoside polyphosphate salts, such as a

Indoloazepines as vasopressin receptor antagonists

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

FIELD OF THE INVENTION This invention relates to novel tricyclic vasopressin receptor antagonists. By interrupting the binding of the peptide hormone vasopressin to its receptors, the antagonists are useful for treating conditions involving increased vascular resistance and cardiac

Tricyclic benzodiazepines as vasopressin receptor antagonists

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

This invention relates to novel tricyclic vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions involving increased vascular resistance and

Tricyclic benzodiazepines as vasopressin receptor antagonists

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

FIELD OF THE INVENTION This invention relates to novel tricyclic vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions involving increased

[1,4]benzodiazepines as vasopressin V2 receptor antagonists

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

FIELD OF THE INVENTION This invention is directed to certain novel [1,4]benzodiazepine compounds, their synthesis, and their use as vasopressin V2 receptor antagonists. More particularly, the compounds of the present invention interfere with the binding of the peptide hormone, vasopressin, to its

Substituted spirobenzazepines

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted spirobenzazepines useful as, for example, vasopressin receptor antagonists. BACKGROUND OF THE INVENTION Vasopressin is a nonpeptide hormone that is secreted primarily from the posterior pituitary gland. The hormone effects

Substituted spiroheterocycles

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted spiroheterobenzazepines useful as, for example, vasopressin receptor antagonists. BACKGROUND OF THE INVENTION Vasopressin is a nonapeptide hormone that is secreted primarily from the posterior pituitary gland. The hormone

Substituted spiroheterocycles

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted spiroheterobenzazepines useful as, for example, vasopressin receptor antagonists. BACKGROUND OF THE INVENTION Vasopressin is a nonapeptide hormone that is secreted primarily from the posterior pituitary gland. The hormone

Nonpeptide substituted benzothiazepines as vasopressin antagonists

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions

Nonpeptide substituted spirobenzoazepines as vasopressin antagonists

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions

Nonpeptide substituted spirobenzoazepines as vasopressin antagonists

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions

Nonpeptide substituted spirobenzoazepines as vasopressin antagonists

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions

Nonpeptide substituted spirobenzoazepines as vasopressin antagonists

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions

Compositions and methods for treating lung disease and injury

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

SEQUENCE LISTING The instant application contains a Sequence Listing, which is entitled QUARK0005US_SeqListing.txt, created on Aug. 30, 2013 and 2280 kb in size, and is hereby incorporated by reference in its entirety. Throughout this application various patents and publications are cited. The

Compositions and methods for treating lung disease and injury

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

SEQUENCE LISTING The instant application contains a Sequence Listing, which is entitled 115340_22802_sequence listing 28OCT15.txt, submitted on Oct. 28, 2015 and 2,279.79 kb in size and is hereby incorporated by reference in its entirety. Throughout this application various patents and publications

fibrosis/bjúgur

P.sup.1-(2'-deoxycytidine 5'-)P.sup.4-(uridine 5'-)tetraphosphate, tetra-(alkali metal) salt, for treating cystic fibrosis

Indoloazepines as vasopressin receptor antagonists

Tricyclic benzodiazepines as vasopressin receptor antagonists

Tricyclic benzodiazepines as vasopressin receptor antagonists

[1,4]benzodiazepines as vasopressin V2 receptor antagonists

Substituted spirobenzazepines

Substituted spiroheterocycles

Substituted spiroheterocycles

Nonpeptide substituted benzothiazepines as vasopressin antagonists

Nonpeptide substituted spirobenzoazepines as vasopressin antagonists

Nonpeptide substituted spirobenzoazepines as vasopressin antagonists

Nonpeptide substituted spirobenzoazepines as vasopressin antagonists

Nonpeptide substituted spirobenzoazepines as vasopressin antagonists

Compositions and methods for treating lung disease and injury

Compositions and methods for treating lung disease and injury

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum